reports
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spo...
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets ma...
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Con...
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "” page of the "" section of the . A replay will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons in immunology to deliver life-changing therapies. We...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinop...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today ...
Celldex Reports Second Quarter 2025 Financial Results and Provides Cor...
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of barzolvolimab in EoE and CIndU and Phase 1 study of CDX-622 in healthy volunteers in 2H 2025 HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second...
Celldex Presents Data Demonstrating Profound Long Term Improvement in ...
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spont...
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phas...
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new dat...
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data...
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress Company to host webcast on Thursday, June 12 at 6:00 pm ET HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast...
Celldex Therapeutics Announces Election of Denice Torres to its Board ...
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice’s extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her ...
Celldex Reports First Quarter 2025 Financial Results and Provides Corp...
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex’s first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc...
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in...
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease Phase 2 study fully enrolled; data expected in 2H 2025 HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting...
Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics to Present at Upcoming Investor Conferences HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "” page of the "" section of the . Replays will be available for 90 days following the event. About Celldex Ther...
Celldex Therapeutics Presents Positive Preclinical Data from Inflammat...
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem ce...
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phas...
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -- 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 - HAMPTON, N.J., March 01, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CL...
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and...
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase 2 PN study Celldex’s first bispecific for inflammatory diseases, CDX-622, Phase 1 study initiated Multiple important data read outs anticipated in 2025 HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results f...
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fundamental processes that ...
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Stu...
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starva...
Celldex Therapeutics Inc: 1 director
A director at Celldex Therapeutics Inc bought 11,500 shares at 26.820USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation Conference on Tuesday, November 12th at 4:00 p.m. ET 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 4:15 p.m. ET Live webcasts of the presentations will be available on the "” page of the "" section of the . Replays will be available for 90 days following the event. About Cel...
Celldex Reports Third Quarter 2024 Financial Results and Provides Corp...
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 week treatment data in landmark, global Phase 2 CSU study demonstrated deepening of response and a favorable safety profile Enrollment continues in Phase 2 PN and EOE studies; Phase 2 AD study to start in Q4 Celldex’s first bispecific for inflammatory diseases, CDX-622, to enter the clinic in ...
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoint...
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s Phase 2 clinical tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.